Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Patents
Teva Comments on the Biologics Price Competition and Innovation Act of 2007
July 10th, 2007
Today, the Senate Health, Education, Labor and Pensions committee will take a significant step forward to ensure that the Food and Drug Administration (FDA) has the regulatory pathway necessary to establish an approval process for generic biologics. Teva applauds the Committee, especially Senators Kennedy, Enzi, Clinton and Hatch for their leadership, as well as Senator Schumer, in taking these important steps. The fundamental approach of the Biologics Price Competition and Innovation Act of 2007 is to address the scientific, regulatory and legal issues involved in bringing affordable biologics to the marketplace. The bill will create a scientifically-rigorous, efficient, FDA-driven...
Source: Drug Law Weekly (2007-07-10)
|
